Sat Kartar Life Limited
SATKARTAR (NSE) · SATKARTAR (BSE 212393) · ISIN INE0NB801022 · Pharmaceuticals · listed 2025
Not on any surveillance list
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
No quarterly results stored for this company yet.
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹67.66 cr | ₹2.39 cr | ₹84.18 cr |
| 30 Sep 2025 standalone | ₹58.18 cr | ₹2.26 cr | ₹71.12 cr |
| 31 Mar 2025 standalone | ₹51.5 cr | ₹5.92 cr | ₹63.74 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 63.62% | 0.13% | 2.26% | 36.38% |
Latest filings
- Sat Kartar Life Limited has informed the Exchange about Investor Presentation 25 October 2026 · NSE
- Sat Kartar Life Limited has informed the Exchange regarding a press release dated October 24, 2026, titled "financial performance for the half year ended September 30, 2026.". 24 October 2026 · NSE
- Sat Kartar Life Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 24 October 2026 · NSE
- Sat Kartar Life Limited has informed the Exchange regarding Outcome of Board Meeting held on September 30, 2026. 30 September 2026 · NSE
- Annual Report FY2025-26 (New) 3 August 2026 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Cipla Limited
- Dr. Reddy's Laboratories Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Aurobindo Pharma Limited
- Divi's Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 25 October 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.